Table 1.
Characteristics of the study subjects
| Characteristic | Total cohort | Subgroup* |
|---|---|---|
| Number of subjects (male) |
333 |
174 |
| Age (y), mean ± SD |
68.6 ± 10.4 |
67.1 ± 10.9 |
| Comorbidity, n (%) |
229 (68.8) |
116 (66.7) |
| Comorbid diseases, n (%) |
|
|
| 1. Hypertension |
110 (33.0) |
61 (35.1) |
| 2. Neuropsychiatric |
58 (17.4) |
28 (16.1) |
| 3. Cardiac |
52 (15.6) |
20 (11.5) |
| 4. Endocrine/metabolic |
51 (15.3) |
22 (12.6) |
| 5. Respiratory |
35 (10.5) |
16 (9.2) |
| 6. Malignancy |
23 (6.9) |
12 (6.9) |
| 7. Chronic kidney disease |
22 (6.6) |
10 (5.7) |
| 8. Hepatobiliary |
21 (6.3) |
15 (8.6) |
| 9. Rheumatoid arthritis |
17 (5.1) |
14 (8.0) |
| Fracture history, n (%) |
301 (90.4) |
151 (86.8) |
| Fracture sites, n (%) |
|
|
| Spine |
265 (79.6) |
134 (77.0) |
| Hip |
48 (14.4) |
21 (12.1) |
| Others@ |
21 (6.3) |
8 (4.6) |
| Baseline DXA, n (%) |
94 (28.2) |
60 (34.5) |
| BMD T-score (SD), mean ± SEM |
|
|
| Spine |
−2.0 ± 0.2 |
−1.9 ± 0.2 |
| Femoral neck |
−2.1 ± 0.1 |
−1.9 ± 0.1 |
| Total hip |
−1.7 ± 0.1 |
−1.6 ± 0.2 |
| First prescriber, n (%) |
|
|
| Rheumatology |
140 (42.0) |
85 (48.9) |
| Orthopedics |
101 (30.3) |
37 (21.3) |
| Others# |
92 (27.6) |
52 (29.9) |
| Enrolment criteria |
|
|
| NOF recommendation, n (%) |
282 (84.7) |
144 (82.8) |
| ACR guideline, n (%) |
51 (15.3) |
30 (17.2) |
| Vertebroplasty, n (%) |
11 (3.3) |
6 (3.4) |
| Tobacco use |
1 (0.3) |
0 (0) |
| Alcohol use | 2 (0.6) | 1 (0.6) |
*Subjects with MPR ≥ 80% at year 1; NOF (2008): Clinician's Guide to Prevention and Treatment of Osteoporosis by the National Osteoporosis Foundation (2008); ACR (2001): Recommendations for the treatment and prevention of glucocorticoid-induced osteoporosis by the American College of Rheumatology (2001); DXA: Dual energy X-ray absorptiometry; BMD: bone mineral density; SD: standard deviation; SEM: standard error of the mean; Serum creatinine >1.4 mg/dl; @: including rib, wrist, upper arm and pelvis; #: Physician of Family Medicine, Metabolism, Rehabilitation.